New England Institute for Clinical Research helps conduct T2 Project AD study for Alzheimer’s disease. They presently seek participants for the study in the Stamford, Connecticut region.

The Problem

Alzheimer’s affects more than 5.7 million Americans and this number will grow. The disease, a progressive, degenerative neurologic disease will growth the aging Baby Boomer generation in America. It is the sixth leading cause of death in America

The Study

The T2 Protect AD study has been set up to investigate troriluzole which may protect against slow down and improve memory and thinking problems which increase as Alzheimer’s diseases progress. The study sponsor is Biohaven.

The Clinical Investigator Site: New England Institute for Clinical Research

The New England Institute for Clinical Research positions their research site at the forefront of innovative clinical research—bringing state-of-the-art research programs from the pharmaceutical industry, academia, medical societies and patient advocacy groups to the New England and metro New York community.

Their core research team has participated in over one hundred clinical trials; over 90% of their research endeavors have resulted in the approval by the Food and Drug Administration (FDA) of new devices and oral and injectable medicines for the diagnosis and treatment of a wide array of diseases as reported on their website. An impressive record.

They were co-founded by Angelo Termine and Peter McAllister. They are also known as Ki Health Partners.

Participant Recruitment in Stamford, CT Area

The clinical research investigator site is one of 40 such sites across the country conducting the T2 Protect AD study. They are current inviting candidates to learn more.

What is Troriluzole?

Troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. The compound increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters (i.e. EAAT2) located on glial cells that play a key role in clearing glutamate from the synapse. Glutamate dysfunction is implicated in the pathophysiology of a broad range of disorders including Amyotrophic Lateral Sclerosis (ALS), Spinocerebellar Ataxia (SCA), Alzheimer’s Disease (AD), anxiety, depression, Obsessive-Compulsive Disorder (OCD), chronic pain, and a variety of cancers. The therapeutic potential of troriluzole is supported by clinical and translational research studies conducted with riluzole in a variety of these indications.

Source: GreenWich Time

Pin It on Pinterest